Cancer Patients Find Lasting Relief from Depression with Psilocybin Therapy

Imagine a single treatment offering lasting relief from the crushing weight of depression. For cancer patients battling depression, that reality is closer than ever thanks to a groundbreaking study published in Cancer.

Researchers from Sunstone Therapies conducted a phase 2 trial involving 30 cancer patients also diagnosed with major depressive disorder. The study explored the impact of a single dose of psilocybin, combined with psychological support, on depression and anxiety.

The results are remarkable. Two years after receiving the treatment, over half (53.6%) of the participants experienced a significant and sustained reduction in their depression symptoms, as measured by the Montgomery Asberg Depression Rating Scale. Similarly, a substantial portion (46.4%) saw significant and lasting relief from anxiety, according to the Hamilton Anxiety Rating Scale.

“One dose of psilocybin, coupled with psychological support, provides long-term positive impact, relieving depression for up to two years in a significant number of cancer patients,” explains Dr. Manish Agrawal of Sunstone Therapies. The team is now investigating whether repeating the treatment could further improve outcomes.

While the study offers promising results, it’s important to note that several authors disclosed ties to Sunstone Therapies. Further research is needed to fully understand the long-term effects and potential benefits of this innovative approach.

阅读中文版 (Read Chinese Version)

Disclaimer: This content is aggregated from public sources online. Please verify information independently. If you believe your rights have been infringed, contact us for removal.